Form 4: CytomX Therapeutics Director Zhen Su Granted 38,000 Stock Options

CytomX Therapeutics, Inc. Director Zhen Su has been granted 38,000 stock options with an exercise price of $2.82 per share, aligning executive incentives with shareholder value.

Summary

• Zhen Su, a Director of CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options.
• The stock options have an exercise price of $2.82 per share.
• The options were granted on June 11, 2025, and expire on June 10, 2035.
• The underlying shares subject to the option will vest and become exercisable as to 100% of the total number of shares on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the Issuer's 2026 Annual Meeting of stockholders, contingent on continuous service as a director.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It's a routine compensation event, not indicative of major operational changes.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• Stock options are a common form of executive and director compensation, indicating standard corporate governance practices.

Future Outlook

The stock options granted to Director Zhen Su are set to vest on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of CytomX Therapeutics' stockholders, provided continuous service as a director.

Industry Context

The grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain talent while aligning their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to a director is a common compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to a one-year anniversary or the next annual meeting, is typical for director equity grants, promoting retention and long-term commitment.
• Without specific peer company compensation data, it's difficult to assess the size of this grant (38,000 options) against industry benchmarks, but it appears to be a routine grant for a director.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but it also serves to align the director's interests with shareholder value creation.
• Director (Zhen Su): This grant represents a component of their compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of Stockholders, assuming continuous service.
• Upon vesting, Director Su will have the ability to exercise these options to acquire common stock of CytomX Therapeutics, Inc.

Key Dates

Keywords

CytomX Therapeutics, CTMX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology